News
SDZXF
100.50
NaN%
--
Sandoz announces US launch of Enzeevu 2 mg
TipRanks · 2d ago
Sandoz launches Enzeevu biosimilar for retinal diseases in US
TipRanks · 2d ago
Sandoz launches Ranluspec ranibizumab biosimilar in Europe
TipRanks · 6d ago
Barclays Sticks to Its Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 11/11 07:35
Sandoz launches semaglutide treatment in Brazil
TipRanks · 11/09 06:34
AbbVie: Why I See More Upside After Q3
Seeking Alpha · 10/30 17:39
Barclays Keeps Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 10/29 07:46
Sandoz falls as headwinds in Germany prompt cautious outlook
Seeking Alpha · 10/28 17:06
Sandoz Lifts Margin Guidance as Biosimilars Drive Q3 Growth
TipRanks · 10/28 06:33
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Seeking Alpha · 10/16 12:28
Barclays Sticks to Their Buy Rating for Sandoz Group Ltd (SDZXF)
TipRanks · 10/12 06:27
Sandoz price target raised to CHF 60 from CHF 55 at Morgan Stanley
TipRanks · 10/06 15:55
Barclays Reaffirms Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 10/06 06:35
Sandoz boosts European biosimilar capacity with new Slovenian plant
TipRanks · 09/29 05:32
Sandoz wins Canada nod for generic Ozempic; inks licensing deal for generic Hemlibra
Seeking Alpha · 09/18 12:24
mAbxience, Sandoz sign collaboration agreement for biosimilar access
TipRanks · 09/18 10:25
Sandoz joins mAbxience to develop emicizumab biosimilar and expand haemophilia pipeline
TipRanks · 09/18 05:33
Sandoz Wins Canadian Approval for Generic Semaglutide, Targeting Growing GLP-1 Market
TipRanks · 09/18 05:33
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Seeking Alpha · 09/17 18:21
Sandoz price target raised to CHF 72 from CHF 66 at Berenberg
TipRanks · 09/11 13:35
More
Webull provides a variety of real-time SDZXF stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZXF
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.